A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalating Parallel-Group Study to Investigate the Tolerability of Enecadin (INN) in Acute Ischemic Stroke.
Phase of Trial: Phase II
Latest Information Update: 27 May 2014
At a glance
- Drugs Enecadin (Primary)
- Indications Stroke
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms TEST
- Sponsors PAION
- 21 May 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 14 Nov 2007 Status change
- 03 Feb 2006 New trial record.